Sinovac Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinovac Biotech Ltd.
Having decided to suspend 12 million doses of Sinovac’s coronavirus vaccine, Brazil’s regulatory agency says it will need to make its own on-site assessment of conditions at the Chinese facility that makes the product.
The European drugs regulator has given an overview of progress with the assessment of new vaccine candidates, additional and booster vaccines, and the use of vaccines in younger age groups.
Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?
Coronavirus Notebook: Egypt Boosts Vaccine Supply, Fenofibrate Shows ‘Astounding’ Results In Treating COVID-19
The European Medicines Agency has OKd more production sites for the manufacture of vaccines destined for the EU, the US and Australia have warned against taking ivermectin to protect against SARS-CoV-2 infection, and Italy has dismissed some ‘fake news’ about vaccine approvals.
- In Vitro Diagnostics
- Drug Delivery
- Implantable Devices
- Monitoring Equipment & Devices
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Beijing Kexing Bioproducts
- Sinovac Dalian Vaccine Technology Co., Ltd.
- Sinovac (Cayman) Limited